Ivermectin

— Losing streak continues for controversial antiparasitic by Ed Susman A higher dose of ivermectin given for a longer duration still failed to offer any benefit in mild to moderate COVID-19, data from a large randomized U.S. trial showed. In the ACTIV-6 trial of more...